Deferoxamine
生产企业：App pharmaceuticals llc, Bedford laboratories div ben venue laboratories inc，另有 3 家
Deferoxamine is a chelating agent used to treat iron or aluminum toxicity and some blood transfusion dependent anemias.
Deferoxamine is a chelating agent used to treat iron or aluminum toxicity and some blood transfusion dependent anemias.
Deferoxamine works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming ferrioxamine, a stable complex which is eliminated via the kidneys. 100 mg of deferoxamine is capable of binding approximately 8.5 mg of trivalent (ferric) iron. Deferoxamine works in treating aluminum toxicity by binding to tissue-bound aluminum to form aluminoxamine, a stable, water-soluble complex. The formation of aluminoxamine increases blood concentrations of aluminum, resulting in an increased concentration gradient between the blood and dialysate, boosting the removal of aluminum during dialysis. 100 mg of deferoxamine is capable of binding approximately 4.1 mg of aluminum.
Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.
